“The funding from Cycle for Survival has been instrumental as we search for treatments to help people with ACC. I thank the donors and participants for their outstanding support.”
Alan L. Ho, MD, PhD
Head and Neck Oncology Service
Head and Neck Oncology Service
Problem
Number of new ACC diagnoses in
the U.S. each year:
Idea
How
What's next
You should know:
- Cycle for Survival funding was instrumental for making both the MK-2206 and Regorafenib trials possible.
- The Regorafenib trial is currently enrolling with a goal of including 38 patients total.
- Dr. Ho’s success in receiving research support from the Conquer Cancer Foundation and NIH was in large part made possible by Cycle for Survival providing timely support for these ACC research efforts.
- Dr. Ho is working to build on the preliminary findings from the MK-2206 trial to develop new drug combinations for ACC patients.
- None of this progress would be possible without Cycle for Survival donors and participants who fund cutting-edge trials that combat cancer.